100.00% -0.735

Avenue Therapeutics Inc (ATXI)

Panoramica Notizia Cronologia dei prezzi Financials Perché ATXI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1106)

Biotechnology (623)

Prossima data di guadagno

Ultimi documenti SEC

ATXI's Discussions on Twitter

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATXI Avenue Therapeutics Inc	0.00	0	1.40M	-2.95M	-1.83M	-0.9554
VRTX Vertex Pharmaceuticals Inc	436.27	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.87	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	799.65	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	322.11	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	309.66	34.37B	5.36B	287.73M	924.18M	2.5229

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Stock List: Research Stocks from Around the World - GuruFocus

Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan

フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo

Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart

Rare disease drug wins FDA nod as Fortress unit sells voucher for $205M - Stock Titan

ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView

Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times

Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN

Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com

Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets

Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com

Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com

Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com

Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com South Africa

Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener

Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan

ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech

TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal

Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat

Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights

Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

PKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News

Palvella Therapeutics Announces Proposed Public Offering - GlobeNewswire

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia

Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks

Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com

After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan

Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire

Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Candel Therapeutics Announces Pricing of Public Offering - The Manila Times

Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat

Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan

Anchor Line Partners, LLC and Northwood Investors, LLC secures 98,500 s/f lease Stoke Therapeutics at 245 Fifth Ave. - NEREJ

Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ATXI